Clinical TrialJul 29, 2026, 04:12 PM
Silexion Initiates Phase 2/3 Clinical Trial for SIL204 in Pancreatic Cancer
AI Summary
Silexion Therapeutics Corp. announced the successful initiation of its Phase 2/3 clinical trial for SIL204, its lead siRNA product candidate, in locally advanced pancreatic cancer. The trial commenced at Tel Aviv Sourasky Medical Center, marking the transition from regulatory preparation to active clinical execution. Patient screening is expected to begin in the coming weeks, with first patient dosing to follow, while additional sites in Israel and Germany are also progressing towards activation.
Key Highlights
- Silexion Therapeutics successfully initiated Phase 2/3 clinical trial for SIL204.
- Trial for locally advanced pancreatic cancer commenced at Tel Aviv Sourasky Medical Center.
- Site is now cleared to begin patient screening in the coming weeks.
- First patient dosing is anticipated to follow the screening process.
- Additional Israeli and German trial sites are progressing towards activation.
- SIL204 is designed to silence a broad range of KRAS mutations.
- Pancreatic cancer has a five-year survival rate below 13%.
Price Impact
More from SLXN